XBIO Xenetic Biosciences Inc.

1.88
+0.25  (+15%)
Previous Close 1.63
Open 1.64
Price To Book 0.54
Market Cap 6,211,930
Shares 3,304,218
Volume 428,852
Short Ratio
Av. Daily Volume 302,753

NewsSee all news

  1. Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform
  2. Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering
  3. Xenetic Biosciences Shares Surge After Biotech Prices Common Stock, Warrant Offering
  4. Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
  5. Introducing Xenetic Biosciences (NASDAQ:XBIO), The Stock That Collapsed 98%

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrolment closed in March 2019 due to slow enrolment.
XBIO-101
Endometrial cancer

Latest News

  1. Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform
  2. Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering
  3. Xenetic Biosciences Shares Surge After Biotech Prices Common Stock, Warrant Offering
  4. Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
  5. Introducing Xenetic Biosciences (NASDAQ:XBIO), The Stock That Collapsed 98%
  6. The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings
  7. Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update
  8. Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.
  9. Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update
  10. Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering
  11. Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform
  12. What Investors Should Know About Xenetic Biosciences Inc’s (NASDAQ:XBIO) Financial Strength